肿瘤细胞治疗研究
英文原题：EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma.
EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma.
胶质母细胞瘤是最常见的原发性脑肿瘤。
胶质母细胞瘤是最常见的原发性脑肿瘤。尽管手术技术、化疗和免疫疗法以及放射治疗均取得显著进展，患者结局仍然很差，生存期改善有限。CAR-T 细胞治疗是一种革命性方法，已成为癌症治疗的新支柱。CAR T 细胞治疗在血液系统恶性肿瘤中取得了卓越疗效；但目前仍有多项局限阻碍其成为一线疗法，实体瘤尤为如此。表皮生长因子受体在胶质母细胞瘤中通常扩增，其变体 EGFR variant III 也在胶质母细胞瘤中表达，因此是 CAR T 细胞治疗令人振奋的潜在靶点。尽管临床前研究显示出良好潜力，临床数据却不一致。本综述评估了 EGFR 靶向 CAR T 细胞领域的现状。
Glioblastoma is the most common primary brain tumor. Although there have been significant advances in surgical techniques, chemo and immunotherapies, and radiation therapy, outcomes continue to be devastating for these patients with minimal improvements in survival. Chimeric antigen receptor T cell therapy is a revolutionary approach that is a new pillar in the treatment of cancer. CAR T cell therapy has produced remarkable results in hematological malignancies; however, multiple limitations currently prevent it from being a first-line therapy, especially for solid tumors. Epidermal growth factor receptor is classically amplified in glioblastoma, and a variant, EGFR variant III, is expressed on glioblastoma, making it an exciting potential target for CAR T cell therapy. Although preclinical has exciting potential, clinical data has been heterogeneous. In this review, we assess the state of field of EGFR-targeted CAR T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。
